FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386738332> ?p ?o ?g. }

• W4386738332 abstract "Background: SHR8554 is a novel μ-opioid receptor-biased agonist. It has analgesic effects by selectively activating the G protein-coupled pathway. Additionally, it can weakly activate the ß-arrestin-2 pathway, resulting in a limited number of side effects, such as gastrointestinal inhibition. Previous studies have shown that SHR8554 has good analgesic effects, safety and tolerability, but the pharmacokinetic characteristics of SHR8554 in humans have not been reported. This study was designed to investigate the pharmacokinetics and safety of SHR8554 in healthy Chinese male subjects. Methods: A single 1 mg/41.3 μCi intravenous dose of [14C]SHR8554 was administered to six healthy male subjects. Blood, urine and faecal samples were collected at continuous time points to analyse SHR8554 parent drug levels and their metabolites. The total radioactivity in blood, plasma, urine and faeces was detected by using a liquid scintillation counter. The dynamic changes of SHR8554 and its metabolite concentration were by liquid chromatography-tandem mass spectrometry (LC/MS), and then pharmacokinetic analysis. The safety of the drug on the subjects was also observed after a single intravenous injection. Results: The total recovery of radioactivity in urine and faeces was 99.68% ± 0.79% in 216 h, including 76.22% ± 1.12% in urine and 23.46% ± 1.36% in faeces. Seventeen major metabolites in blood, urine and faeces were analysed and identified. The main metabolic pathways of SHR8554 in the human body involve 1) N-dealkylation; 2) O-deethylation; 3) mono-oxidation; 4) glucuronidation, etc. The primary mechanism of SHR8554 clearance in the human body is through urinary excretion, primarily in its parent drug and metabolite forms. The drug has good safety, and no serious adverse effects were observed. Conclusion: SHR8554 showed favourable pharmacokinetic characteristics and safety profiles in this study. SHR8554 is extensively metabolized in human body. The main metabolic pathways include N-dealkylation and O-deethylation, as well as mono-oxidation and glucuronidation. The main excretion route of SHR8554 and its metabolites is through urine. Clinical Trial Registration: http://www.chinadrugtrials.org.cn/, identifier CTR20220450." @default.
• W4386738332 created "2023-09-15" @default.
• W4386738332 creator A5003675477 @default.
• W4386738332 creator A5010422757 @default.
• W4386738332 creator A5013234657 @default.
• W4386738332 creator A5021930138 @default.
• W4386738332 creator A5022193491 @default.
• W4386738332 creator A5026071162 @default.
• W4386738332 creator A5057313063 @default.
• W4386738332 creator A5067374801 @default.
• W4386738332 creator A5070961992 @default.
• W4386738332 creator A5076038276 @default.
• W4386738332 creator A5083312218 @default.
• W4386738332 date "2023-09-14" @default.
• W4386738332 modified "2023-10-17" @default.
• W4386738332 title "Study of the mass balance, biotransformation and safety of [14C]SHR8554, a novel μ-opioid receptor injection, in healthy Chinese subjects" @default.
• W4386738332 cites W142954314 @default.
• W4386738332 cites W2015087988 @default.
• W4386738332 cites W2109083102 @default.
• W4386738332 cites W2148852974 @default.
• W4386738332 cites W2165671231 @default.
• W4386738332 cites W2321870572 @default.
• W4386738332 cites W2408277066 @default.
• W4386738332 cites W2507665026 @default.
• W4386738332 cites W2514644222 @default.
• W4386738332 cites W2770319189 @default.
• W4386738332 cites W2896951195 @default.
• W4386738332 cites W2899115689 @default.
• W4386738332 cites W2937061546 @default.
• W4386738332 cites W2954614519 @default.
• W4386738332 cites W3026008272 @default.
• W4386738332 cites W3085621672 @default.
• W4386738332 cites W3215347017 @default.
• W4386738332 cites W4307501528 @default.
• W4386738332 doi "https://doi.org/10.3389/fphar.2023.1231102" @default.
• W4386738332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37781692" @default.
• W4386738332 hasPublicationYear "2023" @default.
• W4386738332 type Work @default.
• W4386738332 citedByCount "0" @default.
• W4386738332 crossrefType "journal-article" @default.
• W4386738332 hasAuthorship W4386738332A5003675477 @default.
• W4386738332 hasAuthorship W4386738332A5010422757 @default.
• W4386738332 hasAuthorship W4386738332A5013234657 @default.
• W4386738332 hasAuthorship W4386738332A5021930138 @default.
• W4386738332 hasAuthorship W4386738332A5022193491 @default.
• W4386738332 hasAuthorship W4386738332A5026071162 @default.
• W4386738332 hasAuthorship W4386738332A5057313063 @default.
• W4386738332 hasAuthorship W4386738332A5067374801 @default.
• W4386738332 hasAuthorship W4386738332A5070961992 @default.
• W4386738332 hasAuthorship W4386738332A5076038276 @default.
• W4386738332 hasAuthorship W4386738332A5083312218 @default.
• W4386738332 hasBestOaLocation W43867383321 @default.
• W4386738332 hasConcept C112705442 @default.
• W4386738332 hasConcept C149151106 @default.
• W4386738332 hasConcept C151730666 @default.
• W4386738332 hasConcept C181199279 @default.
• W4386738332 hasConcept C185592680 @default.
• W4386738332 hasConcept C197934379 @default.
• W4386738332 hasConcept C2777477808 @default.
• W4386738332 hasConcept C2778375690 @default.
• W4386738332 hasConcept C2779907587 @default.
• W4386738332 hasConcept C2780026642 @default.
• W4386738332 hasConcept C2780820201 @default.
• W4386738332 hasConcept C55493867 @default.
• W4386738332 hasConcept C61716771 @default.
• W4386738332 hasConcept C71924100 @default.
• W4386738332 hasConcept C86803240 @default.
• W4386738332 hasConcept C87644729 @default.
• W4386738332 hasConcept C98274493 @default.
• W4386738332 hasConceptScore W4386738332C112705442 @default.
• W4386738332 hasConceptScore W4386738332C149151106 @default.
• W4386738332 hasConceptScore W4386738332C151730666 @default.
• W4386738332 hasConceptScore W4386738332C181199279 @default.
• W4386738332 hasConceptScore W4386738332C185592680 @default.
• W4386738332 hasConceptScore W4386738332C197934379 @default.
• W4386738332 hasConceptScore W4386738332C2777477808 @default.
• W4386738332 hasConceptScore W4386738332C2778375690 @default.
• W4386738332 hasConceptScore W4386738332C2779907587 @default.
• W4386738332 hasConceptScore W4386738332C2780026642 @default.
• W4386738332 hasConceptScore W4386738332C2780820201 @default.
• W4386738332 hasConceptScore W4386738332C55493867 @default.
• W4386738332 hasConceptScore W4386738332C61716771 @default.
• W4386738332 hasConceptScore W4386738332C71924100 @default.
• W4386738332 hasConceptScore W4386738332C86803240 @default.
• W4386738332 hasConceptScore W4386738332C87644729 @default.
• W4386738332 hasConceptScore W4386738332C98274493 @default.
• W4386738332 hasLocation W43867383321 @default.
• W4386738332 hasLocation W43867383322 @default.
• W4386738332 hasOpenAccess W4386738332 @default.
• W4386738332 hasPrimaryLocation W43867383321 @default.
• W4386738332 hasRelatedWork W1492229869 @default.
• W4386738332 hasRelatedWork W1964759623 @default.
• W4386738332 hasRelatedWork W1976890451 @default.
• W4386738332 hasRelatedWork W1983466460 @default.
• W4386738332 hasRelatedWork W1996694250 @default.
• W4386738332 hasRelatedWork W1998356222 @default.
• W4386738332 hasRelatedWork W2040155790 @default.
• W4386738332 hasRelatedWork W2056938528 @default.
• W4386738332 hasRelatedWork W2112675484 @default.
• W4386738332 hasRelatedWork W2132691174 @default.

• next